Clinical Trial Update: A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan

View source ↗

Summary

Pfizer is conducting a real-world study of elranatamab for refractory multiple myeloma in Taiwan, which is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)

Snippet

Sponsor: Pfizer | Conditions: Refractory Multiple Myeloma (RRMM) | Status: NOT_YET_RECRUITING